Pembrolizumab for Endometrial Carcinosarcoma

Phase-Based Progress Estimates
Maria Rubinstein, Harrison, NYEndometrial CarcinosarcomaPembrolizumab - Drug
What conditions do you have?

Study Summary

This trial will test whether a combination of two drugs is an effective treatment for endometrial cancer or endometrial carcinosarcoma.

Eligible Conditions
  • Endometrial Carcinosarcoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 2 years

2 years
Frequency of AE's during therapy
24 weeks
Overall response rate (ORR)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Pembrolizumab Second Course
100%Inappropriate antidiuretic hormone secretion
100%Urinary tract infection
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Inappropriate antidiuretic hormone secretion with 100%, Urinary tract infection with 100%.

Trial Design

1 Treatment Group

Pembrolizumab with Olaparib
1 of 1

Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Pembrolizumab with OlaparibExperimental Group · 2 Interventions: Pembrolizumab, Olaparib · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,845 Previous Clinical Trials
589,990 Total Patients Enrolled
2 Trials studying Endometrial Carcinosarcoma
104 Patients Enrolled for Endometrial Carcinosarcoma
Merck Sharp & Dohme LLCIndustry Sponsor
3,706 Previous Clinical Trials
4,964,032 Total Patients Enrolled
Maria Rubinstein, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 18+ · Female Participants · 14 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can participate if you had a previous or current cancer that doesn't affect the safety or effectiveness of the study treatment.
You have received treatment for endometrial cancer before, but no more than three different types of treatments.
If you have taken hormonal therapy before, it will not be considered as a prior treatment for this study.

Frequently Asked Questions

Are there any unfilled slots for participants in this trial?

"Verified. According to, this medical study has initiated recruitment and is searching for 25 participants at 7 locations. It was posted on January 27th 2022 and its last update occurred on October 21st 2022." - Anonymous Online Contributor

Unverified Answer

What medical conditions have been found to be ameliorated by Pembrolizumab?

"Pembrolizumab is the go-to therapy for those with unresectable melanoma, as well as individuals facing a high risk of recurrence or microsatellite instability." - Anonymous Online Contributor

Unverified Answer

How many sites are engaged in this research endeavor?

"At present, 7 medical centres are contributing to this study. These sites include Middletown, Basking Ridge and Montvale as well as 4 other locations. To minimize any travel requirements, it is recommended that participants select the closest site to them for enrollment." - Anonymous Online Contributor

Unverified Answer

Is this a groundbreaking research endeavor?

"After AstraZeneca's initial research into pembrolizumab began in 2005, the drug was granted its Phase 1 approval. Nowadays, 1114 studies are underway for this medication at 3058 different locations and 66 countries." - Anonymous Online Contributor

Unverified Answer

To what extent has Pembrolizumab been tested in other scientific experiments?

"Currently, 1114 clinical trials are researching the efficacy of Pembrolizumab with 143 studies at Phase 3. Out of all the locations conducting these experiments, Houston Texas is a major hub - though there are 42751 operating sites around the world." - Anonymous Online Contributor

Unverified Answer

What is the enrollment capacity for this clinical experiment?

"Affirmative. According to, this trial is now open for enrollment and was initially published on January 27th 2022 with the most recent update occurring October 21st of that same year. 25 study participants are needed between 7 distinct medical centres." - Anonymous Online Contributor

Unverified Answer

What potential adverse reactions might one experience while using Pembrolizumab?

"The safety of pembrolizumab is estimated to be a 2, taking into account the findings of this Phase 2 trial. Although data confirming its efficacy has yet to emerge, there are studies that support its relative safeness." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.